Annual EBIT
-$312.30 M
+$658.73 M+67.84%
31 December 2023
Summary:
Alnylam Pharmaceuticals annual earnings before interest & taxes is currently -$312.30 million, with the most recent change of +$658.73 million (+67.84%) on 31 December 2023. During the last 3 years, it has risen by +$458.81 million (+59.50%). ALNY annual EBIT is now -7296.87% below its all-time high of -$4.19 million.ALNY EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$74.29 M
-$96.38 M-436.28%
30 September 2024
Summary:
Alnylam Pharmaceuticals quarterly earnings before interest & taxes is currently -$74.29 million, with the most recent change of -$96.38 million (-436.28%) on 30 September 2024. Over the past year, it has dropped by -$255.92 million (-140.90%). ALNY quarterly EBIT is now -140.90% below its all-time high of $181.63 million, reached on 30 September 2023.ALNY Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$186.88 M
-$255.92 M-370.67%
30 September 2024
Summary:
Alnylam Pharmaceuticals TTM earnings before interest & taxes is currently -$186.88 million, with the most recent change of -$255.92 million (-370.67%) on 30 September 2024. Over the past year, it has increased by +$196.18 million (+51.21%). ALNY TTM EBIT is now -370.67% below its all-time high of $69.04 million, reached on 30 June 2024.ALNY TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ALNY EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +67.8% | -140.9% | +51.2% |
| 3 y3 years | +59.5% | +54.7% | +73.3% |
| 5 y5 years | +58.9% | +64.4% | +76.1% |
ALNY EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +67.8% | -140.9% | +79.6% | -370.7% | +81.6% |
| 5 y | 5 years | at high | +67.8% | -140.9% | +79.6% | -370.7% | +81.6% |
| alltime | all time | -7296.9% | +67.8% | -140.9% | +79.6% | -370.7% | +81.6% |
Alnylam Pharmaceuticals EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$74.29 M(-436.3%) | -$186.88 M(-370.7%) |
| June 2024 | - | $22.09 M(-178.0%) | $69.04 M(-135.0%) |
| Mar 2024 | - | -$28.33 M(-73.4%) | -$197.22 M(-36.8%) |
| Dec 2023 | -$312.30 M(-67.8%) | -$106.35 M(-158.6%) | -$312.30 M(-18.5%) |
| Sept 2023 | - | $181.63 M(-174.4%) | -$383.06 M(-58.8%) |
| June 2023 | - | -$244.17 M(+70.3%) | -$929.55 M(+1.3%) |
| Mar 2023 | - | -$143.41 M(-19.0%) | -$917.44 M(-5.5%) |
| Dec 2022 | -$971.02 M(+36.9%) | -$177.11 M(-51.5%) | -$971.02 M(-4.6%) |
| Sept 2022 | - | -$364.86 M(+57.2%) | -$1.02 B(+24.6%) |
| June 2022 | - | -$232.06 M(+17.8%) | -$816.51 M(+10.4%) |
| Mar 2022 | - | -$196.99 M(-11.9%) | -$739.36 M(+4.3%) |
| Dec 2021 | -$709.12 M(-8.0%) | -$223.49 M(+36.3%) | -$709.12 M(+1.2%) |
| Sept 2021 | - | -$163.96 M(+5.8%) | -$700.72 M(-7.9%) |
| June 2021 | - | -$154.91 M(-7.1%) | -$760.48 M(+0.6%) |
| Mar 2021 | - | -$166.76 M(-22.5%) | -$756.22 M(-1.9%) |
| Dec 2020 | -$771.10 M(-12.9%) | -$215.08 M(-3.9%) | -$771.10 M(-7.4%) |
| Sept 2020 | - | -$223.72 M(+48.5%) | -$832.61 M(+1.8%) |
| June 2020 | - | -$150.66 M(-17.1%) | -$817.81 M(-7.7%) |
| Mar 2020 | - | -$181.65 M(-34.3%) | -$885.68 M(-0.8%) |
| Dec 2019 | -$885.25 M(+16.4%) | -$276.58 M(+32.4%) | -$892.82 M(+14.1%) |
| Sept 2019 | - | -$208.93 M(-4.4%) | -$782.60 M(-5.5%) |
| June 2019 | - | -$218.52 M(+15.7%) | -$828.22 M(+3.3%) |
| Mar 2019 | - | -$188.79 M(+13.5%) | -$802.06 M(+5.4%) |
| Dec 2018 | -$760.67 M(+52.1%) | -$166.36 M(-34.6%) | -$760.67 M(+2.6%) |
| Sept 2018 | - | -$254.56 M(+32.3%) | -$741.62 M(+21.0%) |
| June 2018 | - | -$192.35 M(+30.5%) | -$612.86 M(+13.3%) |
| Mar 2018 | - | -$147.41 M(+0.1%) | -$540.98 M(+8.2%) |
| Dec 2017 | -$500.09 M(+17.8%) | -$147.30 M(+17.1%) | -$500.09 M(+6.8%) |
| Sept 2017 | - | -$125.80 M(+4.4%) | -$468.22 M(+4.3%) |
| June 2017 | - | -$120.47 M(+13.1%) | -$449.09 M(+6.7%) |
| Mar 2017 | - | -$106.51 M(-7.7%) | -$421.07 M(-0.8%) |
| Dec 2016 | -$424.59 M(+43.4%) | -$115.43 M(+8.2%) | -$424.59 M(+5.7%) |
| Sept 2016 | - | -$106.68 M(+15.4%) | -$401.67 M(+7.6%) |
| June 2016 | - | -$92.45 M(-16.0%) | -$373.32 M(+5.5%) |
| Mar 2016 | - | -$110.03 M(+18.9%) | -$353.81 M(+19.5%) |
| Dec 2015 | -$296.01 M(+60.7%) | -$92.51 M(+18.1%) | -$296.01 M(+18.8%) |
| Sept 2015 | - | -$78.33 M(+7.4%) | -$249.21 M(+15.3%) |
| June 2015 | - | -$72.94 M(+39.7%) | -$216.08 M(+12.5%) |
| Mar 2015 | - | -$52.22 M(+14.2%) | -$192.03 M(+4.2%) |
| Dec 2014 | -$184.21 M(+98.2%) | -$45.71 M(+1.1%) | -$184.21 M(+9.6%) |
| Sept 2014 | - | -$45.20 M(-7.6%) | -$168.09 M(+8.4%) |
| June 2014 | - | -$48.90 M(+10.1%) | -$155.13 M(+21.6%) |
| Mar 2014 | - | -$44.41 M(+50.1%) | -$127.55 M(+37.2%) |
| Dec 2013 | -$92.94 M | -$29.59 M(-8.2%) | -$92.94 M(+7.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2013 | - | -$32.23 M(+51.2%) | -$86.70 M(+19.4%) |
| June 2013 | - | -$21.31 M(+117.4%) | -$72.62 M(+14.6%) |
| Mar 2013 | - | -$9.80 M(-58.0%) | -$63.37 M(-0.3%) |
| Dec 2012 | -$63.57 M(+16.0%) | -$23.35 M(+28.7%) | -$63.57 M(+18.2%) |
| Sept 2012 | - | -$18.15 M(+50.4%) | -$53.80 M(+11.9%) |
| June 2012 | - | -$12.07 M(+20.7%) | -$48.09 M(-2.1%) |
| Mar 2012 | - | -$10.00 M(-26.4%) | -$49.14 M(-10.4%) |
| Dec 2011 | -$54.82 M(+25.3%) | -$13.59 M(+9.2%) | -$54.82 M(+2.8%) |
| Sept 2011 | - | -$12.44 M(-5.2%) | -$53.31 M(+7.5%) |
| June 2011 | - | -$13.12 M(-16.3%) | -$49.60 M(+3.1%) |
| Mar 2011 | - | -$15.68 M(+29.8%) | -$48.11 M(+10.0%) |
| Dec 2010 | -$43.74 M(-7.0%) | -$12.08 M(+38.4%) | -$43.74 M(+13.2%) |
| Sept 2010 | - | -$8.73 M(-24.9%) | -$38.63 M(-2.3%) |
| June 2010 | - | -$11.63 M(+2.8%) | -$39.55 M(-21.4%) |
| Mar 2010 | - | -$11.31 M(+62.3%) | -$50.33 M(+7.1%) |
| Dec 2009 | -$47.01 M(+90.6%) | -$6.97 M(-27.8%) | -$47.01 M(+5.2%) |
| Sept 2009 | - | -$9.65 M(-56.9%) | -$44.68 M(+16.8%) |
| June 2009 | - | -$22.41 M(+180.9%) | -$38.26 M(+33.4%) |
| Mar 2009 | - | -$7.98 M(+72.1%) | -$28.68 M(+16.3%) |
| Dec 2008 | -$24.66 M(-68.8%) | -$4.64 M(+43.4%) | -$24.66 M(+177.8%) |
| Sept 2008 | - | -$3.23 M(-74.8%) | -$8.88 M(-84.4%) |
| June 2008 | - | -$12.83 M(+224.3%) | -$56.98 M(-3.6%) |
| Mar 2008 | - | -$3.96 M(-135.5%) | -$59.10 M(-25.3%) |
| Dec 2007 | -$79.14 M(+100.3%) | $11.15 M(-121.7%) | -$79.14 M(-21.1%) |
| Sept 2007 | - | -$51.34 M(+243.3%) | -$100.28 M(+74.3%) |
| June 2007 | - | -$14.95 M(-37.7%) | -$57.54 M(+7.2%) |
| Mar 2007 | - | -$23.99 M(+140.2%) | -$53.70 M(+35.9%) |
| Dec 2006 | -$39.50 M(-9.1%) | -$9.99 M(+16.1%) | -$39.50 M(-11.1%) |
| Sept 2006 | - | -$8.60 M(-22.5%) | -$44.43 M(-4.4%) |
| June 2006 | - | -$11.11 M(+13.4%) | -$46.49 M(-0.2%) |
| Mar 2006 | - | -$9.80 M(-34.3%) | -$46.59 M(+7.2%) |
| Dec 2005 | -$43.47 M(+34.7%) | -$14.92 M(+39.8%) | -$43.47 M(+27.5%) |
| Sept 2005 | - | -$10.67 M(-4.8%) | -$34.09 M(+14.2%) |
| June 2005 | - | -$11.20 M(+67.7%) | -$29.84 M(+16.5%) |
| Mar 2005 | - | -$6.68 M(+20.8%) | -$25.61 M(-20.6%) |
| Dec 2004 | -$32.26 M(+57.8%) | -$5.53 M(-13.9%) | -$32.26 M(-31.8%) |
| Sept 2004 | - | -$6.43 M(-7.9%) | -$47.31 M(+15.8%) |
| June 2004 | - | -$6.97 M(-47.7%) | -$40.84 M(+14.6%) |
| Mar 2004 | - | -$13.33 M(-35.2%) | -$35.65 M(+51.2%) |
| Dec 2003 | -$20.45 M(+384.3%) | -$20.58 M(<-9900.0%) | -$23.59 M(+684.6%) |
| Sept 2003 | - | $44.00 K(-102.5%) | -$3.01 M(-1.4%) |
| June 2003 | - | -$1.78 M(+40.9%) | -$3.05 M(+140.9%) |
| Mar 2003 | - | -$1.27 M | -$1.27 M |
| Dec 2002 | -$4.22 M | - | - |
FAQ
- What is Alnylam Pharmaceuticals annual earnings before interest & taxes?
- What is the all time high annual EBIT for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals annual EBIT year-on-year change?
- What is Alnylam Pharmaceuticals quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals quarterly EBIT year-on-year change?
- What is Alnylam Pharmaceuticals TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals TTM EBIT year-on-year change?
What is Alnylam Pharmaceuticals annual earnings before interest & taxes?
The current annual EBIT of ALNY is -$312.30 M
What is the all time high annual EBIT for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high annual earnings before interest & taxes is -$4.19 M
What is Alnylam Pharmaceuticals annual EBIT year-on-year change?
Over the past year, ALNY annual earnings before interest & taxes has changed by +$658.73 M (+67.84%)
What is Alnylam Pharmaceuticals quarterly earnings before interest & taxes?
The current quarterly EBIT of ALNY is -$74.29 M
What is the all time high quarterly EBIT for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high quarterly earnings before interest & taxes is $181.63 M
What is Alnylam Pharmaceuticals quarterly EBIT year-on-year change?
Over the past year, ALNY quarterly earnings before interest & taxes has changed by -$255.92 M (-140.90%)
What is Alnylam Pharmaceuticals TTM earnings before interest & taxes?
The current TTM EBIT of ALNY is -$186.88 M
What is the all time high TTM EBIT for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high TTM earnings before interest & taxes is $69.04 M
What is Alnylam Pharmaceuticals TTM EBIT year-on-year change?
Over the past year, ALNY TTM earnings before interest & taxes has changed by +$196.18 M (+51.21%)